Verition Fund Management LLC lowered its stake in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) by 22.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 36,166 shares of the company’s stock after selling 10,543 shares during the quarter. Verition Fund Management LLC owned approximately 0.10% of Lucid Diagnostics worth $55,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. LPL Financial LLC bought a new position in Lucid Diagnostics during the second quarter worth about $33,000. Bank of Montreal Can bought a new position in Lucid Diagnostics during the second quarter worth about $35,000. Millennium Management LLC bought a new position in Lucid Diagnostics during the second quarter worth about $55,000. State Street Corp boosted its position in Lucid Diagnostics by 24.4% during the first quarter. State Street Corp now owns 56,693 shares of the company’s stock worth $190,000 after purchasing an additional 11,121 shares during the period. Finally, Geneos Wealth Management Inc. bought a new position in Lucid Diagnostics during the first quarter worth about $209,000. Institutional investors own 5.89% of the company’s stock.
Analyst Upgrades and Downgrades
LUCD has been the subject of a number of research reports. BTIG Research cut their target price on shares of Lucid Diagnostics from $5.00 to $3.50 and set a “buy” rating for the company in a research report on Friday, November 18th. Needham & Company LLC lowered their price target on shares of Lucid Diagnostics from $4.25 to $3.10 and set a “buy” rating on the stock in a report on Tuesday, November 15th.
Lucid Diagnostics Trading Down 6.1 %
About Lucid Diagnostics
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
- Get a free copy of the StockNews.com research report on Lucid Diagnostics (LUCD)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Want to see what other hedge funds are holding LUCD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating).
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.